The pharmacogenetics of antidepressant treatments for depressive disorders

Min-Soo Lee

Research output: Contribution to journalReview articlepeer-review

6 Citations (Scopus)


Pharmacological treatments for depressive disorder vary between individuals, with 30-40% of patients not responding sufficiently to antidepressant drugs. Different genetic makeups are thought to play an important role in the actions of antidepressants, but there are presently no gold-standard genetic markers for determining the response to antidepressants. In this report, we review the work focused on the association between antidepressant responses and genetic polymorphisms, including in the serotonin transporter, tryptophan hydroxylase, serotonin receptor 2A, serotonin receptor 6, G-protein β subunit, and the norepinephrine transporter.

Original languageEnglish
Pages (from-to)170-178
Number of pages9
JournalDrug Development Research
Issue number3
Publication statusPublished - 2005 Jul 1


  • Depression
  • Norepinephrine transporter
  • Pharmacogenetics
  • Serotonin transporter
  • Tryptophan hydroxylase

ASJC Scopus subject areas

  • Drug Discovery
  • Organic Chemistry
  • Pharmacology

Fingerprint Dive into the research topics of 'The pharmacogenetics of antidepressant treatments for depressive disorders'. Together they form a unique fingerprint.

Cite this